Scott Liu Shi-kau, co-founder and CEO of Shanghai Henlius Biotech, which listed on the Hong Kong stock exchange on Wednesday. Photo: Tory Ho Scott Liu Shi-kau, co-founder and CEO of Shanghai Henlius Biotech, which listed on the Hong Kong stock exchange on Wednesday. Photo: Tory Ho
Scott Liu Shi-kau, co-founder and CEO of Shanghai Henlius Biotech, which listed on the Hong Kong stock exchange on Wednesday. Photo: Tory Ho
Pharmaceuticals

How a son made it his mission to launch inexpensive drugs in China after father’s death from cancer

  • Shanghai Henlius Biotech, backed by Chinese conglomerate Fosun, lists in Hong Kong
  • Henlius’ HLX01 ‘biosimilar’ to treat non-Hodgkin lymphoma is the first such generic drug approved in China

Topic |   Pharmaceuticals
Scott Liu Shi-kau, co-founder and CEO of Shanghai Henlius Biotech, which listed on the Hong Kong stock exchange on Wednesday. Photo: Tory Ho Scott Liu Shi-kau, co-founder and CEO of Shanghai Henlius Biotech, which listed on the Hong Kong stock exchange on Wednesday. Photo: Tory Ho
Scott Liu Shi-kau, co-founder and CEO of Shanghai Henlius Biotech, which listed on the Hong Kong stock exchange on Wednesday. Photo: Tory Ho
READ FULL ARTICLE